InflaRx has developed highly specific protoype and humanized monoclonal antibodies targeting activation products of the complement system in collaboration with Beijing Mabworks Biotech Co. Ltd, a company supported by two of the leading immunologist in China. InflaRx has made new break through discoveries in this area of research resulting in a new class of antibodies with exceptional blocking activities for their respective target within the complement field.
InflaRx´ lead drug candidate (IFX-1) targeting complement has successfully completed clinical trial phase I, within less than 4 years development. This project is supported by the BMBF (German Ministry of Education and Research) - Grant Nr. 0315115.
InflaRx plans clinical phase II trials in Germany and Europe in collaboration with the Department of Anesthesiology and Intensive Care Therapy at the Friedrich-Schiller-University in Jena, which has longstanding experience in clinical trial design and multi center trials within the area of acute care and the sepsis indication.
Pictures: Inflarx GmbH